Clinical Trials
29
Trial Phases
3 Phases
Drug Approvals
6
Clinical Trials
Distribution across different clinical trial phases (28 trials with phase data)• Click on a phase to view related trials
CATCH-R: A Rollover Study to Provide Continued Access to Rucaparib
- Conditions
- Ovarian CancerPeritoneal CancerEpithelial Ovarian CancerOther Solid TumorMetastatic Castration-Resistant Prostate CancerFallopian Tube Cancer
- Interventions
- First Posted Date
- 2020-12-21
- Last Posted Date
- 2024-05-07
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 34
- Registration Number
- NCT04676334
- Locations
- 🇨🇦
London Regional Cancer Centre, London, Ontario, Canada
🇨🇦Institut De Recherche De L'Hospital D'Ottawa, Ottawa, Ontario, Canada
🇨🇦Princess Margaret Hospital - Toronto, Toronto, Ontario, Canada
Study of Oral Rucaparib With Other Anticancer Agents in Metastatic Castration Resistant Prostate Cancer Patients (RAMP)
- Conditions
- Metastatic Castration Resistant Prostate Cancer
- Interventions
- First Posted Date
- 2019-11-27
- Last Posted Date
- 2023-06-29
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 8
- Registration Number
- NCT04179396
- Locations
- 🇺🇸
Piedmont Cancer Institute, P.C., Atlanta, Georgia, United States
🇺🇸University of Minnesota, Minneapolis, Minnesota, United States
🇺🇸Urology Associates, P.C., Nashville, Tennessee, United States
A Study to Evaluate Rucaparib in Participants With Solid Tumors and With Deleterious Mutations in HRR Genes
- First Posted Date
- 2019-11-21
- Last Posted Date
- 2023-10-02
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 83
- Registration Number
- NCT04171700
- Locations
- 🇺🇸
UCLA Medicine Hematology and Oncology, Los Angeles, California, United States
🇺🇸UCSF Helen Diller Family Comprehensive Cancer Center, San Francisco, California, United States
🇺🇸Florida Cancer Specialists, Saint Petersburg, Florida, United States
A Disease Registry Encompassing the Care Of Patients With Multiple Myeloma on Panobinostat
- Conditions
- Multiple Myeloma
- First Posted Date
- 2019-11-04
- Last Posted Date
- 2023-06-15
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 248
- Registration Number
- NCT04150289
- Locations
- 🇺🇸
American Health Network Indiana, Indianapolis, Indiana, United States
🇺🇸Southern Nevada Cancer Research Foundation and Optum Cancer Care, Las Vegas, Nevada, United States
🇺🇸Oncology Specialists of Charlotte, Charlotte, North Carolina, United States
A Study to Evaluate Rucaparib in Combination With Other Anticancer Agents in Participants With a Solid Tumor (SEASTAR)
- Conditions
- Triple-negative Breast CancerOvarian CancerUrothelial CarcinomaSolid Tumor
- Interventions
- First Posted Date
- 2019-06-20
- Last Posted Date
- 2024-01-16
- Lead Sponsor
- pharmaand GmbH
- Target Recruit Count
- 25
- Registration Number
- NCT03992131
- Locations
- 🇺🇸
Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Sarah Cannon Research Institute, Nashville, Tennessee, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- Next